Advertisement

Medical Oncology

, Volume 22, Issue 4, pp 359–366 | Cite as

Gemictabine plus carboplatin in patients with advanced non-small cell lung cancer

  • Se Hoon Park
  • Seong Hwan Jeong
  • Sun Young Kyung
  • Young-Hee Lim
  • Chang Hyeok An
  • Sang Pyo Lee
  • Jeong Woong Park
  • Soo Mee Bang
  • Eun Kyung Cho
  • Dong Bok Shin
  • Jae Hoon Lee
Original Article

Abstract

To evaluate the efficacy and safety of gemictabine combined with carboplatin for a chemotherapy regimen for patients with metastatic, recurrent, or locally advanced non-small cell lung cancer (NSCLC), 46 chemotherapy-naïve patients with histologically confirmed stage IIIB or IV NSCLC were treated with 1250 mg/m2 of gemictabine on d 1 and 8, with carboplatin of AUC 6 additionally applied on d 1. This treatment was repeated every 3 wk. In all, a total of 215 chemotherapy courses were administered. The median age of the patients was 46, ranging from 33 to 83. Ten patients (22%) had an ECOG performance status of 2. Responses were observed objectively in 20 patients (43.5%) and maintained for a median of 7.4 mo. The median duration of progression-free and overall survivals were 5.0 and 12.3 mo, respectively. Neutropenia was frequently encountered, and gastrointestinal side effects, such as anorexia and nausea, were mostly predictable but manageable. One patient died of septic shock due to a complication with pneumonia while simultaneously trying to recover from myelosuppression. A subgroup consisting of patients aged 65 yr or older and/or PS 2 showed a outcome similar with the entire group of all patients involved in the study: response rate (43.5%), median PFS (4.6 months), median OS (12.3 months), and similar toxicity rate. After analyzing all the results, it was evident that a treatment of gemcitabine combined with carboplatin is an active and safe regimen for first-line treatment of advanced NSCLC. The results of the elderly and/or PS 2 patients were similar to those of the entire group of patients.

Key Words

Non-small cell lung cancer chemotherapy gemcitabine carboplatin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Souquet PJ, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899–909.Google Scholar
  3. 3.
    Anderson H, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447–453.PubMedCrossRefGoogle Scholar
  4. 4.
    Wozniak AJ, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459–2465.PubMedGoogle Scholar
  5. 5.
    Sandler AB, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122–130.PubMedGoogle Scholar
  6. 6.
    Bonomi P, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623–631.PubMedGoogle Scholar
  7. 7.
    Cardenal F, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 12–18.PubMedGoogle Scholar
  8. 8.
    Crino L, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522–3530.PubMedGoogle Scholar
  9. 9.
    Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999; 80: 815–820.PubMedCrossRefGoogle Scholar
  10. 10.
    Lees M, et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325–337.PubMedCrossRefGoogle Scholar
  11. 11.
    Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999; 4: 241–251.PubMedGoogle Scholar
  12. 12.
    Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Luedke DW, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 1990; 8: 886–891.PubMedGoogle Scholar
  14. 14.
    Gridelli C, et al. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicentre randomised trial. The “Gruppo Oncologico Centro-Sud-Isole” (G.O.C.S.I.). Ann Oncol 1996; 7: 821–826.PubMedGoogle Scholar
  15. 15.
    Bunn PA, Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989; 16: 27–33.PubMedGoogle Scholar
  16. 16.
    Klastersky J, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556–1562.PubMedGoogle Scholar
  17. 17.
    Maestu I, et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 2003; 42: 345–354.PubMedCrossRefGoogle Scholar
  18. 18.
    Domine M, et al. Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Semin Oncol 2001; 28(3 Suppl 10): 4–9.PubMedGoogle Scholar
  19. 19.
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710–1717.PubMedGoogle Scholar
  20. 20.
    Simon R. Designs for efficient clinical trials. Oncology (Huntingt) 1989; 3: 43–49; discussion 51–53.Google Scholar
  21. 21.
    Anton A, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1998; 22: 139–148.PubMedCrossRefGoogle Scholar
  22. 22.
    Lippe P, et al. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. Ann Oncol 1999; 10: 217–221.PubMedCrossRefGoogle Scholar
  23. 23.
    Pirker R, et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer. Ann Oncol 1995; 6: 833–835.PubMedGoogle Scholar
  24. 24.
    Mazzanti P, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003; 41: 81–89.PubMedCrossRefGoogle Scholar
  25. 25.
    Zatloukal P, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41: 321–331.PubMedCrossRefGoogle Scholar
  26. 26.
    Rudd RM, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23: 142–153.PubMedCrossRefGoogle Scholar
  27. 27.
    Frasci G. Chemotherapy of lung cancer in the elderly. Crit Rev Oncol Hematol 2002; 41: 349–361.PubMedGoogle Scholar
  28. 28.
    Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000; 14: 193–212; x–xi.PubMedCrossRefGoogle Scholar
  29. 29.
    Langer CJ, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173–181.PubMedGoogle Scholar
  30. 30.
    Kelly K, et al. Should older patients receive combination chemotherapy for advanced non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20: 329a (abstr 1313).Google Scholar
  31. 31.
    Lilenbaum RC, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190–196.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  • Se Hoon Park
    • 1
  • Seong Hwan Jeong
    • 1
  • Sun Young Kyung
    • 1
  • Young-Hee Lim
    • 1
  • Chang Hyeok An
    • 1
  • Sang Pyo Lee
    • 1
  • Jeong Woong Park
    • 1
  • Soo Mee Bang
    • 1
  • Eun Kyung Cho
    • 1
  • Dong Bok Shin
    • 1
  • Jae Hoon Lee
    • 1
  1. 1.Division of Hematooncology, Department of Internal Medicine, Gachon Medical SchoolGil Medical CenterIncheonSouth Korea

Personalised recommendations